Four weeks of isometric handgrip training results in lower awake ambulatory blood pressure compared with control: a randomized clinical trial.

Clin Physiol Funct ImagingOct 27, 2026

Patrícia C Oliveira, Gustavo Waclawovsky, Alexandre M Lehnen

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial compared handgrip and knee-extension isometric training with control in 67 adults with controlled hypertension receiving antihypertensive medication. Participants completed 12 supervised sessions over 4 weeks. Only the handgrip group differed significantly from control in awake ambulatory blood pressure: systolic pressure was 121.8 ± 3.1 vs. 124.2 ± 2.6 mmHg, and diastolic pressure was 76.3 ± 3.6 vs. 80.8 ± 4.2 mmHg. No significant group differences were found for 24-hour or sleep blood pressure, or between the exercise groups.

Key findings

  • Awake systolic blood pressure was lower with handgrip training than control (121.8 ± 3.1 vs. 124.2 ± 2.6 mmHg; p = 0.017).
  • Awake diastolic blood pressure was lower with handgrip training than control (76.3 ± 3.6 vs. 80.8 ± 4.2 mmHg; p = 0.009).
  • Knee-extension training did not differ significantly from control, and no significant differences were found for 24-h or sleep blood pressure.

Why it matters

The findings suggest that a brief, supervised handgrip isometric programme may be associated with modest reductions in awake ambulatory blood pressure in medicated adults with controlled hypertension. The absence of a detectable advantage for knee-extension training indicates that recruiting more muscle mass did not produce superior blood pressure outcomes in this trial.

What to keep in mind

The intervention lasted 4 weeks and involved 67 participants; the reported blood pressure differences were limited to awake measurements.

Source

Published in Clin Physiol Funct Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.